AstraZeneca's fair value estimate has nudged up to about $150.26 from roughly $146.44, even as the long run revenue growth ...
Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback